What happened
Pharmicell reported separate results for FY2025: revenue of US$78M (+75.8% year on year), operating profit of US$23.5M (+637.6% year on year) and net income of US$27.6M (+536.9% year on year).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$78M |
|---|---|
| Revenue vs a year earlier | +75.8% |
| Operating profit | US$23.5M |
| Net income | US$27.6M |
| Period | FY2025 (separate) |
| Filed | 2026-02-09, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260209800310 → open original filing |
Source: DART. Information only, not investment advice.